Skip to main content

Menveo FDA Approval History

FDA Approved: Yes (First approved February 19, 2010)
Brand name: Menveo
Generic name: meningococcal conjugate vaccine
Company: GlaxoSmithKline
Treatment for: Meningococcal Disease Prophylaxis

Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

Development timeline for Menveo

DateArticle
Oct 17, 2022Approval FDA Approves Menveo in a New Single-Vial Presentation to Help Prevent Disease Caused by Meningococcal Bacteria Serogroups A, C, Y, and W
Aug  2, 2013Approval FDA Expands Age Indication for Menveo
Jan 31, 2011Approval FDA Approves the Novartis Quadrivalent Meningococcal Conjugate Vaccine, Menveo, for Use in Children From 2 Years of Age
Feb 22, 2010Approval Novartis Gets US Approval for Menveo Meningitis Vaccine
Jul  1, 2009Novartis Receives Complete Response Letter From The US Food And Drug Administration For Its Investigational Vaccine Menveo

See also

Menveo (meningococcal conjugate vaccine) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer